BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

credentis ag Opens the Gates to the North American Market


9/25/2012 10:48:43 AM

September, 25th 2012 -- After receiving the European market release for Curodont™ in January 2012, a further milestone for the internationalisation of credentis ag was fulfilled. In September 2012, credentis passed the two-day inspection of DQS on behalf of Health Canada.

credentis ag has met the high quality standards set by Health Canada without any non- conformities. During this intensive inspection, the quality management system of credentis was successfully inspected. As a result, credentis is now allowed to receive the import licence for Canada and to market its ground-breaking product Curodont™ for the regeneration of defect teeth in Canada.

With this milestone, credentis is able to enter the North American market!

About Curodont™ and Self-Assembling Peptides

Curodont™ is based on the patented “Self-Assembling Peptide”- technology. The technology enables the formation of a three-dimensional matrix in an almost closed environment. The matrix itself acts as a scaffold for tissue regeneration, e.g. the formed matrix enables de-novo formation of Calciumphosphate crystals within an initial carious lesion.

Curodont™, with its main component the self-assembling peptide P11-4, is the first product of credentis that has obtained market approval (CE-label).

Curodont™ provides dentists with a novel technology for in depth regeneration rather than repair of caries and similar tooth decay. Applied to an initial carious lesion, Curodont™ forms a scaffold of small fibres within the lesion. Around these fibres new enamel or dentin can form and grow. Ideally, within several weeks, the lesion will regenerate without the use of the dental drill or a filler material.

About credentis ag

credentis ag has its headquarters in the Technopark Aargau Switzerland, Windisch; the young team was voted #33 of Top Swiss Startups 2011 and was one of the Swiss Venture Leaders 2011.

CEO Dominik Lysek and CTO Michael Hug have expert knowledge in medicinal technology and a strong network in the dental industry. Dr. Werner Berner (member of the board) and Dr. Erich Platzer (chairman of the board), both members of the StartAngels Network, perfectly complement the know-how of the managem

Contact: Dr. Dominik Lysek, CEO, tel +41 56 560 2044; info@credentis.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES